Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2016

View Archived Issues

Phase III trial to establish biosimilarity of SB8 to bevacizumab

Sarepta Therapeutics initiates phase III trial of SRP-4045 and SRP-4053 for the treatment of DMD

FDA grants emergency use authorization for Zika virus molecular detection assay

GVK Biosciences patents TrKA inhibitors

Arvinas discloses PROTAC compounds

Johns Hopkins University describes agents for the treatment of cancer

Newave Pharmaceutical develops FGFR4 inhibitors

Oncbiomune Pharmaceuticals enrolls patients for phase Ia study of Proscavax

University of Washington presents micro-dystrophins

Antibe Therapeutics completes phase II trial of ATB-346

Lycera begins enrollment in phase II trial of LYC-30937-EC in active ulcerative colitis

Armanezumab shows promise for AD

Immune mechanisms of the Mtb deltappe25-pe19 vaccine candidate

BioLineRx collaborates with MD Anderson Cancer Center for phase II study of BL-8040

Windtree receives grant to support Aerosurf phase IIb trial

Valeant licenses rights to develop and commercialize NER-1006 from Norgine

Alkermes submits sNDA to FDA for extended-release formulation of Aristada

Coherus BioSciences reports topline results for phase III study of CHS-1420

Selumetinib does not meet primary endpoint in phase III SELECT-1 trial

Proteostasis Therapeutics completes key preclinical milestone in collaboration with Astellas

Scintilla Pharmaceuticals acquires Scilex Pharmaceuticals to bolster pain management business

COMP grants orphan drug designation to AB Science's masitinib in ALS

FDA confirms sufficient data to advance E-2609 into phase III studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...